Search

Magnesium acetate

Meplazumab

Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

Olopatadine

An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations

Dexmethylphenidate

Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193].

Elosulfase alfa

The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. … Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome.

Mifepristone

Currently under investigation for use in psychotic depression (phase 3 trials). … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.

Epoprostenol

It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

Pazopanib

It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Haloperidol

[A180625] The efficacy of haloperidol was first established in controlled trials in the 1960s.[A180610] … However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo.

Recombinant stabilized RSV B prefusion F antigen

[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.